Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naosuikang is a Traditional Chinese Medicine (TCM) formulation, typically administered as a capsule, developed by the Shenzhen Traditional Chinese Medicine Hospital. It is primarily indicated for the treatment of vascular dementia, particularly in patients presenting with the TCM syndrome of spleen-kidney deficiency accompanied by phlegm and blood stasis. The therapeutic approach of Naosuikang involves tonifying the spleen and kidney, resolving phlegm, and promoting blood circulation to improve cognitive function. It has been evaluated in clinical trials in China, comparing its efficacy and safety against nimodipine, a standard treatment for cognitive impairment of vascular origin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Naosuikang.